145 related articles for article (PubMed ID: 20048279)
1. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Padhan P
Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048279
[No Abstract] [Full Text] [Related]
2. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Hebert LA; Rovin BH
Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048278
[No Abstract] [Full Text] [Related]
3. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
Levine SM
Ann Intern Med; 2010 Jan; 152(1):65; author reply 65. PubMed ID: 20048281
[No Abstract] [Full Text] [Related]
4. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
Kötter I
Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
[No Abstract] [Full Text] [Related]
5. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
[TBL] [Abstract][Full Text] [Related]
6. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
[TBL] [Abstract][Full Text] [Related]
7. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
[TBL] [Abstract][Full Text] [Related]
8. [Cyclophosphamide in ANCA associated vasculitis: continuous oral vs pulse therapy].
Serpieri N
G Ital Nefrol; 2010; 27(6):566. PubMed ID: 21132637
[No Abstract] [Full Text] [Related]
9. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
[TBL] [Abstract][Full Text] [Related]
10. [Long-term data from the CYCLOPS study].
Haubitz M
Z Rheumatol; 2013 May; 72(4):402-3. PubMed ID: 23552980
[No Abstract] [Full Text] [Related]
11. [Diffuse pulmonary hemorrhage associated with antineutrophil cytoplasmic antibodies. Findings of high-resolution computerized tomography. A case report].
Galeotti R; Sala S; Rosina G; Mannella P
Radiol Med; 1997 Dec; 94(6):685-7. PubMed ID: 9524614
[No Abstract] [Full Text] [Related]
12. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
13. The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.
Menahem S; Hiremagalur B; Mudge D; Toussaint N; Walters G;
Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S24-36. PubMed ID: 18713121
[No Abstract] [Full Text] [Related]
14. [Diagnosis und therapy of ANCA-associated vasculitis].
Aries PM; Hellmich B; Gross WL
Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569
[TBL] [Abstract][Full Text] [Related]
15. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
Flossmann O; de Groot K
Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
[No Abstract] [Full Text] [Related]
16. The antineutrophil cytoplasmic antibody-associated vasculitides.
Seo P; Stone JH
Am J Med; 2004 Jul; 117(1):39-50. PubMed ID: 15210387
[TBL] [Abstract][Full Text] [Related]
17. [Initial results of multicenter, randomized, controlled therapy studies for ANCA-associated vasculitis].
de Groot K
Z Rheumatol; 2003 Apr; 62(2):116-7. PubMed ID: 12820617
[No Abstract] [Full Text] [Related]
18. [ANCA-positive vasculitis of the skin and kidneys associated with acne conglobata].
Manz B; Rytter M; Mittag M; Seidel W; Nenoff P
Hautarzt; 2002 Nov; 53(11):730-4. PubMed ID: 12402135
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
Tervaert JW; Stegeman CA
Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
[TBL] [Abstract][Full Text] [Related]
20. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
Jayne DR; Rasmussen N
Mayo Clin Proc; 1997 Aug; 72(8):737-47. PubMed ID: 9276602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
